INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.15 HKD | +1.56% |
|
+17.92% | -8.42% |
| Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
| Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 43.85 | 48.45 | 46.70 |
| Spread/Res. | -10.72% | -19.20% | -16.17% |
| Spread/Supp. | +17.92% | +30.07% | +32.26% |
| Support | 33.20 | 30.10 | 29.60 |
Technical Rankings Surperformance
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- 1801 Stock
- Charts Innovent Biologics, Inc.
